Care starts with the cause of the soreness

Home care fits soreness without locking or giving way

Pause the motion that clearly caused the flare. Keep other comfortable activity in the day, since too much rest can add stiffness. Bend and straighten the joint slowly within comfort. Increase walking only after soreness eases. If swelling grows afterward, shorten the next walk.

Write down the activity, sore place and later response. Those notes give the person examining you useful facts.

QC Kinetix provides non-surgical choices

During a QC Kinetix visit, regenerative treatments mean office care without surgery that can use platelets taken from your blood. PRP is the short name for platelet-rich plasma. Staff first take blood and spin it to separate platelets. They place that portion into the aching joint with a needle. Concentrated PRP uses a larger platelet amount. The medical providers at this office check the joint and perform care.

The aim is help with soreness, not a promise to replace missing cartilage. Ask how long activity limits last. Also ask how care would change if soreness remains.

Surgery may matter when loose tissue blocks the joint

A loose flap, repeated locking or one deep damaged area may lead to a surgical opinion. Microfracture surgery opens small holes in bone so tough repair tissue can fill the damage. Another operation takes a cartilage-and-bone plug from a less-used part of the knee or from a donor. A surgeon fits the plug into the damaged spot. Other surgery removes some cartilage cells, grows them outside the body and returns them later.

Healing often takes months. Ask when the leg may carry all body weight and when driving, stairs, lifting and work can resume.

Urgent symptoms don't belong in routine joint care

Quick medical care is needed when fever comes with joint heat and swelling. If an injury makes standing impossible or very painful, seek help. A newly swollen calf after surgery or office care can signal a blood clot. It needs prompt medical care. Locking or fast-worsening soreness also calls for care sooner than a regular visit.

Steady soreness without those signs can wait for a planned exam. Bring current medicines and the scan report.

Sources

1. A JBJS evidence-based review of chondral lesions of the knee sets management by lesion size, location, limb alignment and rotation, and patient demand rather than by product: osteochondral autograft transfer is described as durable and predictable for smaller lesions (under 2 cm2) in young active patients, while lesions of 2 cm2 or more are typically treated with osteochondral allograft transplantation, particulated juvenile articular cartilage, or matrix-associated chondrocyte implantation, with favourable mid- and long-term results reported for allograft or MACI in large lesions of 3 cm2 or more.

   Dekker TJ, et al. — Chondral Lesions of the Knee: An Evidence-Based Approach.. J Bone Joint Surg Am, 2021. DOI: 10.2106/JBJS.20.01161.

2. The Cochrane review of surgical interventions for isolated cartilage defects of the knee in adults found only three randomised trials, all comparing mosaicplasty with microfracture, reporting 133 participants in total with a mean defect area of 2.8 cm2. It found NO randomised trials of allograft transplantation or drilling at all, judged every trial at high or unclear risk of bias, and rated the quality of evidence very low for every outcome.

   Gracitelli GC, et al. — Surgical interventions (microfracture, drilling, mosaicplasty, and allograft transplantation) for treating isolated cartilage defects of the knee in adults.. Cochrane Database Syst Rev, 2016. DOI: 10.1002/14651858.CD010675.pub2.

3. A prospective cohort of 110 patients treated with microfracture for a focal chondral defect was evaluated at a median of 12 years. Scores improved significantly from baseline and did not differ from the 5-year results, but 43 patients had needed further knee surgery including seven knee replacements, 50 had a poor long-term outcome, and normal knee function was generally not achieved. The authors called for caution in recommending microfracture.

   Solheim E, et al. — Results at 10-14 years after microfracture treatment of articular cartilage defects in the knee.. Knee Surg Sports Traumatol Arthrosc, 2016. DOI: 10.1007/s00167-014-3443-1.

4. A systematic review of 13 studies covering 821 athletes treated with microfracture in the knee found good or excellent results in 67%, return to sport in 66% at an average of eight months, return to competition at the pre-injury level in 67% of those - and declining function in 42% of athletes between two and five years after surgery.

   Mithoefer K, et al. — Clinical Outcome and Return to Competition after Microfracture in the Athlete's Knee: An Evidence-Based Systematic Review.. Cartilage, 2010. DOI: 10.1177/1947603510366576.

5. Sixty competitive athletes (mean age 24.3) with a symptomatic knee cartilage lesion were randomised to mosaic osteochondral autologous transplantation or microfracture. At a mean 37 months, 96% of the transplantation group had excellent or good results versus 52% after microfracture.

   Gudas R, et al. — A prospective randomized clinical study of mosaic osteochondral autologous transplantation versus microfracture for the treatment of osteochondral defects in the knee joint in young athletes.. Arthroscopy, 2005. DOI: 10.1016/j.arthro.2005.06.018.

6. At 10 years in the same randomised athlete cohort, osteochondral autologous transplantation remained significantly better than microfracture, with 4 failures (14%) after transplantation versus 11 (38%) after microfracture. Both groups' scores had declined from their earlier peak, and Kellgren-Lawrence grade I changes were present in 25% of the transplantation group and 48% of the microfracture group.

   Gudas R, et al. — Ten-year follow-up of a prospective, randomized clinical study of mosaic osteochondral autologous transplantation versus microfracture for the treatment of osteochondral defects in the knee joint of athletes.. Am J Sports Med, 2012. DOI: 10.1177/0363546512458763.

7. FDA biologics licence BL 125603 (Vericel) describes MACI verbatim as "an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults." The licensed indication is a two-stage surgical implantation for full-thickness DEFECTS of the knee in adults. It is not an injection, it is not licensed for osteoarthritis, and it is not licensed for any joint other than the knee.

   U.S. Food and Drug Administration — MACI (autologous cultured chondrocytes on porcine collagen membrane). FDA, Center for Biologics Evaluation and Research, 2024.

8. In the SUMMIT randomised trial, 144 patients with at least one symptomatic Outerbridge grade III-IV knee defect of 3 cm2 or more (mean lesion 4.8 cm2, mean age 33.8) were randomised to MACI or microfracture. At two years, improvements in KOOS pain (37.0 to 82.5 versus 35.5 to 70.9) and function (14.9 to 60.9 versus 12.6 to 48.7) were significantly greater with MACI.

   Saris D, et al. — Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.. Am J Sports Med, 2014. DOI: 10.1177/0363546514528093.

9. In the RESTORE randomised trial, 288 people aged 50 or over with symptomatic mild-to-moderate medial knee osteoarthritis received three weekly injections of leukocyte-poor PRP or saline placebo. At 12 months there was no significant difference in knee pain (-2.1 versus -1.8 points) and none in medial tibial cartilage VOLUME (-1.4% versus -1.2%). Twenty-nine of 31 prespecified secondary outcomes also showed no difference.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

10. FDA's consumer alert states verbatim of stem cell products, exosome products, adipose-derived stromal vascular fraction, umbilical cord blood, Wharton's Jelly and amniotic fluid products: "None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain." The only stem cell products carrying FDA licensure are blood-forming cells derived from umbilical cord blood, licensed only for disorders of blood production, and there are currently no licensed exosome products.

    U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, Consumers (Biologics), 2020.

11. Pooling 16 of 30 studies covering 868 patients, non-operative management of osteochondral lesions of the TALUS achieved clinical success in 45% of patients (95% CI 40% to 50%) at a median 37 months, with radiographic progression of ankle osteoarthritis in 9% (95% CI 6% to 14%). Roughly half of these lesions do acceptably without an operation.

    Buck TMF, et al. — Non-operative management for osteochondral lesions of the talus: a systematic review of treatment modalities, clinical- and radiological outcomes.. Knee Surg Sports Traumatol Arthrosc, 2023. DOI: 10.1007/s00167-023-07408-w.